Trial Profile

Targeting the B Cell Response to Treat Antibody-Mediated Rejection With Carfilzomib and Belatacept (CarBel)

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belatacept (Primary) ; Carfilzomib (Primary) ; Mycophenolate; Prednisone; Tacrolimus
Indications Renal transplant rejection
Focus Adverse reactions
Acronyms CarBel

Most Recent Events

10 Mar 2026 Planned number of patients changed from 100 to 25.
10 Mar 2026 Planned initiation date changed from 15 Jan 2026 to 15 Apr 2026.
10 Mar 2026 Status changed from recruiting to not yet recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com